HH
BEAM icon

Hilltop Holdings’s Beam Therapeutics BEAM Stock Holding History

Hilltop Holdings’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,450
Closed -$213K – 594
2021
Q3 		$213K Hold
2,450
– – 0.02% 555
2021
Q2 		$315K Buy
+2,450
New +$195K 0.04% 446

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Hilltop Holdings's BEAM Position: Q4 2021 in Review

Hilltop Holdings sold out of Beam Therapeutics (BEAM) in Q4 2021, closing a stake of 2,450 shares — an estimated $213K sold.

Hilltop Holdings first reported a position in BEAM in Q2 2021 and held it in 2 quarters. The position peaked at $315K in Q2 2021. 232 funds tracked by Wall St. Rank hold BEAM as of Q4 2021.

  • Hilltop Holdings reported no remaining Beam Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Hilltop Holdings sold 2,450 Beam Therapeutics shares in Q4 2021, an estimated $213K.
  • Hilltop Holdings first reported a position in Beam Therapeutics in Q2 2021 and held it in 2 quarters.
  • Hilltop Holdings's Beam Therapeutics position peaked at $315K in Q2 2021.
  • 232 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2021.

Based on Hilltop Holdings's 13F filing for Q4 2021, filed 14 Feb 2022.